Day One Biopharmaceuticals IncNASDAQ:DAWN
- LAST PRICE12.5400
- TODAY'S CHANGE (%)0.0500 (0.4003%)
- Bid / Lots12.2800/ 1
- Ask / Lots13.2000/ 1
- Open / Previous Close12.3100 / 12.4900
- Day Range
- 52 Week Range
- Volume668,674
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DAWN |
|---|---|---|
| 09:32 ET | 9568 | 12.44 |
| 09:34 ET | 1116 | 12.32 |
| 09:36 ET | 570 | 12.325 |
| 09:38 ET | 700 | 12.35 |
| 09:39 ET | 470 | 12.37 |
| 09:41 ET | 150 | 12.31 |
| 09:43 ET | 671 | 12.35 |
| 09:45 ET | 1300 | 12.38 |
| 09:48 ET | 200 | 12.38 |
| 09:50 ET | 3565 | 12.43 |
| 09:52 ET | 100 | 12.43 |
| 09:54 ET | 2200 | 12.41 |
| 09:56 ET | 202 | 12.42 |
| 09:57 ET | 1510 | 12.43 |
| 09:59 ET | 381 | 12.45 |
| 10:01 ET | 100 | 12.44 |
| 10:03 ET | 700 | 12.49 |
| 10:06 ET | 100 | 12.49 |
| 10:08 ET | 240 | 12.49 |
| 10:10 ET | 1487 | 12.49 |
| 10:12 ET | 100 | 12.46 |
| 10:14 ET | 1250 | 12.49 |
| 10:17 ET | 976 | 12.52 |
| 10:19 ET | 1562 | 12.55 |
| 10:21 ET | 15651 | 12.485 |
| 10:24 ET | 600 | 12.49 |
| 10:26 ET | 200 | 12.485 |
| 10:28 ET | 1510 | 12.49 |
| 10:30 ET | 200 | 12.485 |
| 10:32 ET | 774 | 12.49 |
| 10:35 ET | 194 | 12.48 |
| 10:37 ET | 410 | 12.5 |
| 10:42 ET | 945 | 12.52 |
| 10:44 ET | 100 | 12.5212 |
| 10:46 ET | 600 | 12.535 |
| 10:51 ET | 668 | 12.57 |
| 10:55 ET | 482 | 12.54 |
| 10:57 ET | 673 | 12.5 |
| 11:00 ET | 2931 | 12.51 |
| 11:02 ET | 307 | 12.48 |
| 11:04 ET | 409 | 12.5 |
| 11:06 ET | 400 | 12.5007 |
| 11:09 ET | 569 | 12.495 |
| 11:11 ET | 100 | 12.5 |
| 11:13 ET | 400 | 12.49 |
| 11:15 ET | 1000 | 12.5 |
| 11:18 ET | 826 | 12.52 |
| 11:20 ET | 200 | 12.53 |
| 11:22 ET | 100 | 12.54 |
| 11:24 ET | 300 | 12.53 |
| 11:26 ET | 1739 | 12.54 |
| 11:29 ET | 200 | 12.53 |
| 11:31 ET | 103 | 12.525 |
| 11:33 ET | 797 | 12.5 |
| 11:36 ET | 600 | 12.5 |
| 11:40 ET | 301 | 12.485 |
| 11:44 ET | 200 | 12.465 |
| 11:45 ET | 900 | 12.45 |
| 11:47 ET | 100 | 12.465 |
| 11:51 ET | 200 | 12.46 |
| 11:54 ET | 100 | 12.465 |
| 11:56 ET | 100 | 12.4654 |
| 11:58 ET | 4584 | 12.525 |
| 12:03 ET | 1403 | 12.53 |
| 12:05 ET | 1000 | 12.5327 |
| 12:09 ET | 2893 | 12.51 |
| 12:14 ET | 200 | 12.505 |
| 12:16 ET | 150 | 12.5 |
| 12:18 ET | 400 | 12.49 |
| 12:20 ET | 162 | 12.48 |
| 12:23 ET | 1335 | 12.5 |
| 12:30 ET | 100 | 12.49 |
| 12:34 ET | 200 | 12.48 |
| 12:36 ET | 495 | 12.49 |
| 12:38 ET | 1188 | 12.51 |
| 12:39 ET | 100 | 12.5 |
| 12:41 ET | 538 | 12.5 |
| 12:43 ET | 3162 | 12.51 |
| 12:45 ET | 110 | 12.515 |
| 12:48 ET | 200 | 12.515 |
| 12:50 ET | 301 | 12.52 |
| 12:52 ET | 1015 | 12.5299 |
| 12:54 ET | 900 | 12.505 |
| 12:56 ET | 100 | 12.505 |
| 12:57 ET | 400 | 12.49 |
| 01:03 ET | 700 | 12.495 |
| 01:06 ET | 150 | 12.5 |
| 01:10 ET | 858 | 12.5 |
| 01:12 ET | 2496 | 12.5 |
| 01:14 ET | 100 | 12.51 |
| 01:17 ET | 642 | 12.52 |
| 01:19 ET | 100 | 12.53 |
| 01:24 ET | 100 | 12.52 |
| 01:26 ET | 887 | 12.505 |
| 01:28 ET | 201 | 12.505 |
| 01:30 ET | 600 | 12.49 |
| 01:33 ET | 1300 | 12.52 |
| 01:37 ET | 200 | 12.51 |
| 01:39 ET | 800 | 12.54 |
| 01:44 ET | 2680 | 12.55 |
| 01:48 ET | 250 | 12.54 |
| 01:50 ET | 100 | 12.54 |
| 01:51 ET | 185 | 12.54 |
| 01:53 ET | 850 | 12.55 |
| 01:55 ET | 300 | 12.56 |
| 01:57 ET | 1645 | 12.57 |
| 02:00 ET | 830 | 12.56 |
| 02:02 ET | 578 | 12.53 |
| 02:04 ET | 2003 | 12.55 |
| 02:06 ET | 500 | 12.555 |
| 02:08 ET | 100 | 12.55 |
| 02:09 ET | 300 | 12.56 |
| 02:11 ET | 400 | 12.56 |
| 02:13 ET | 2503 | 12.62 |
| 02:18 ET | 4163 | 12.67 |
| 02:20 ET | 600 | 12.66 |
| 02:22 ET | 1750 | 12.68 |
| 02:26 ET | 100 | 12.67 |
| 02:27 ET | 200 | 12.67 |
| 02:29 ET | 1001 | 12.67 |
| 02:31 ET | 800 | 12.67 |
| 02:33 ET | 2373 | 12.7 |
| 02:36 ET | 547 | 12.7 |
| 02:38 ET | 400 | 12.695 |
| 02:40 ET | 2519 | 12.705 |
| 02:42 ET | 100 | 12.7 |
| 02:44 ET | 100 | 12.7 |
| 02:45 ET | 100 | 12.7 |
| 02:47 ET | 2517 | 12.695 |
| 02:49 ET | 1753 | 12.69 |
| 02:51 ET | 29351 | 12.635 |
| 02:54 ET | 20338 | 12.68 |
| 02:56 ET | 200 | 12.7 |
| 02:58 ET | 3948 | 12.66 |
| 03:02 ET | 4763 | 12.61 |
| 03:03 ET | 117760 | 12.65 |
| 03:05 ET | 2533 | 12.63 |
| 03:07 ET | 1849 | 12.59 |
| 03:09 ET | 1420 | 12.5354 |
| 03:12 ET | 900 | 12.55 |
| 03:14 ET | 256 | 12.545 |
| 03:16 ET | 350 | 12.56 |
| 03:18 ET | 1261 | 12.5605 |
| 03:20 ET | 1455 | 12.55 |
| 03:21 ET | 201 | 12.55 |
| 03:23 ET | 200 | 12.56 |
| 03:25 ET | 1400 | 12.56 |
| 03:27 ET | 504 | 12.57 |
| 03:30 ET | 649 | 12.57 |
| 03:32 ET | 400 | 12.569 |
| 03:34 ET | 1134 | 12.57 |
| 03:36 ET | 3550 | 12.56 |
| 03:38 ET | 1987 | 12.575 |
| 03:39 ET | 2036 | 12.57 |
| 03:41 ET | 538 | 12.565 |
| 03:43 ET | 400 | 12.56 |
| 03:45 ET | 2450 | 12.55 |
| 03:48 ET | 1690 | 12.56 |
| 03:50 ET | 1142 | 12.56 |
| 03:52 ET | 5676 | 12.6 |
| 03:54 ET | 3897 | 12.595 |
| 03:56 ET | 5699 | 12.55 |
| 03:57 ET | 5970 | 12.52 |
| 03:59 ET | 17902 | 12.54 |
May 30, 2024
Press Release: Day One Announces Sale of Priority Review Voucher for $108 Million, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesDay One Announces Sale of Priority Review Voucher for $108 Million, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Day One Biopharmaceuticals Inc | 1.1B | -5.0x | --- |
Autolus Therapeutics PLC | 1.1B | -3.6x | --- |
Tyra Biosciences Inc | 1.0B | -12.0x | --- |
Enliven Therapeutics Inc | 984.9M | -11.4x | --- |
Verona Pharma PLC | 983.5M | -16.9x | --- |
Disc Medicine Inc | 967.1M | -11.6x | --- |
Company Information
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.
Contact Information
- Headquarters
- 2000 Sierra Point Parkway, Suite 501BRISBANE, CA, United States 94080-1930
- Phone
- 650-484-0899
- Fax
- 302-636-5454
Executives
- Independent Non-Executive Chairman of the Board
- Garry Nicholson
- President, Chief Executive Officer, Director
- Jeremy Bender
- Chief Financial Officer, Chief Operating Officer, Secretary
- Charles York
- General Counsel
- Adam Dubow
- Co-Founder and Head of Research and Development
- Samuel Blackman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 87.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.50 |
Book Value | $3.97 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
